EDIT
Price
$1.64Alerts
Change
-$0.07 (-4.09%)
Updated
Nov 20 closing price
Capitalization
394.7M
97 days until earnings call
Intraday BUY SELL Signals
FATE
Price
$0.92Alerts
Change
-$0.09 (-8.91%)
Updated
Nov 20 closing price
Capitalization
219.87M
101 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs FATE

EDIT vs FATE Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
Nov 20, 2026

Which Stock Would AI Choose? Editas Medicine (EDIT) vs. Fate Therapeutics (FATE) Stock Comparison

Key Takeaways

  • Both EDIT and FATE are clinical-stage biotech companies with no approved products, making them high-risk, catalyst-driven equities whose valuations hinge on pipeline progress.
  • EDIT has shown stronger relative momentum in recent months, supported by a clearer near-term clinical catalyst as its lead candidate advances toward a Phase 1/2 trial.
  • FATE benefits from actual early patient data in autoimmune disease, but has traded with elevated volatility and weaker recent price action.
  • Tickeron AI Verdict: Based on trend consistency, catalyst timing, and relative positioning, the AI currently favors EDIT over FATE.
  • Both companies rely on cash reserves and capital raises to fund operations, and neither is forecast to reach profitability in the near term.
  • You can dig deeper into each ticker's EDIT Major News and EDIT Today's Price Move, as well as FATE Major News and FATE Today's Price Move, for real-time updates and broader context.
  • To see how automated strategies are positioning across the market right now, explore Trending AI Robots.

Introduction

Investors and traders evaluating speculative biotechnology names often look for companies with differentiated platforms, defined catalysts, and sufficient capital to reach the next milestone. Editas Medicine (EDIT) and Fate Therapeutics (FATE) both fit that profile, yet they operate in distinct corners of the sector. This stock comparison is relevant for growth-oriented traders and long-term investors who follow early-stage drug development, are comfortable with binary clinical outcomes, and want a clearer view of how each company's relative performance and market positioning stack up in the current environment.

EDIT Overview and Recent Performance

Editas Medicine is a clinical-stage genome-editing company based in Cambridge, Massachusetts, focused on CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology. After discontinuing its reni-cel sickle cell and beta-thalassemia program in late 2024 and cutting its workforce substantially, the company pivoted to an in vivo (inside the body) gene-editing strategy. Its lead candidate, EDIT-401, is designed to durably lower LDL cholesterol (low-density lipoprotein, or "bad" cholesterol) for patients with hyperlipidemia.

In recent weeks, EDIT has reported progress on EDIT-401, including approval to initiate a Phase 1/2 study and plans to begin patient dosing. The company also delivered quarterly results that topped consensus revenue estimates, supported in part by collaboration milestones. Sentiment has been reinforced by analyst coverage, with several firms maintaining favorable ratings. While the stock remains well below historical highs, its year-to-date relative performance has outpaced the broader biotech sector, and the company has extended its cash runway to fund operations well into 2027.

FATE Overview and Recent Performance

Fate Therapeutics is a clinical-stage biopharmaceutical company based in San Diego that develops off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSCs). Its lead product candidate, FT819, is an allogeneic CAR T-cell therapy targeting CD19, currently being evaluated in autoimmune diseases such as systemic lupus erythematosus (SLE). The company also has earlier-stage programs including FT839, a dual-CAR candidate.

In recent market activity, FATE has presented encouraging early clinical data, including broader patient access and favorable tolerability observations for FT819. The company secured a grant to support a lupus nephritis trial and entered an at-the-market sales agreement to raise additional capital, while management has projected an operating runway into 2028. However, the stock has displayed elevated volatility — moving sharply in both directions — and its recent price action has been comparatively weaker, reflecting both sector-wide pressure and investor sensitivity to ongoing losses and dilution risk.

Trending AI Robots

Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots drawn from a broader library of hundreds of automated strategies that trade thousands of different tickers. Rather than listing every available bot, the page highlights only those whose performance, risk profile, and trading style are best suited to current market conditions. These bots vary widely in strategy, timeframe, win rate, and the specific tickers they trade, so investors can compare options that align with their own approach. For traders weighing names like EDIT and FATE, reviewing the Trending AI Robots section can offer a data-driven perspective on how automated systems are positioning amid shifting sentiment.

Head-to-Head Comparison

Although both companies are pre-revenue biotechs, their business models and risk profiles differ meaningfully. EDIT is a gene-editing platform play whose value rests on a preclinical-to-early-clinical lead asset and a longer runway to proof-of-concept data. FATE is an off-the-shelf cell therapy company with clinical-stage data already in hand, but with a more complex manufacturing and regulatory path.

On momentum, EDIT has generally shown steadier, more positive relative performance, while FATE has traded with higher week-to-week volatility. From a catalyst standpoint, EDIT offers a nearer-term inflection point tied to trial initiation, whereas FATE's catalysts are more dependent on accumulating clinical data readouts. Both carry dilution and financing risk, but FATE has recently leaned more heavily on at-the-market share sales. Sector exposure is similar — both are sensitive to broader biotech sentiment — yet their distinct platforms mean they respond to different scientific and regulatory developments.

Tickeron AI Verdict

Weighing observable factors such as trend consistency, the timing and clarity of near-term catalysts, financing posture, and relative price positioning, Tickeron's AI currently leans toward EDIT as the more favored of the two. The reasoning reflects EDIT's steadier recent momentum and a more defined near-term milestone, versus FATE's elevated volatility and comparatively weaker recent action. This assessment is probabilistic rather than definitive, and should be viewed as one input among many in a broader decision-making process rather than a standalone recommendation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
EDIT vs. FATE commentary
Nov 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and FATE is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for EDIT with price predictions
Nov 20, 2026

Momentum Indicator for EDIT turns negative, indicating new downward trend

EDIT saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 78 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 44 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 121 of 154 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.596). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for FATE with price predictions
Nov 20, 2026

FATE in -12.48% downward trend, sliding for three consecutive days on November 20, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where FATE declined for three days, in 305 of 338 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FATE as a result. In 81 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

The Moving Average Convergence Divergence Histogram (MACD) for FATE turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 45 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

The Aroon Indicator for FATE entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where FATE advanced for three days, in 214 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

FATE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.433) is normal, around the industry mean (3.596). P/E Ratio (-1.748) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (45.045) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. FATE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
EDIT vs FATE: Fundamental Ratings
EDIT
FATE
OUTLOOK RATING
1..100
6854
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
8590
P/E GROWTH RATING
1..100
3214
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (50) in the Biotechnology industry is in the same range as EDIT (53). This means that FATE’s stock grew similarly to EDIT’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that FATE’s stock grew similarly to EDIT’s over the last 12 months.

FATE's SMR Rating (98) in the Biotechnology industry is in the same range as EDIT (99). This means that FATE’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (85) in the Biotechnology industry is in the same range as FATE (90). This means that EDIT’s stock grew similarly to FATE’s over the last 12 months.

FATE's P/E Growth Rating (14) in the Biotechnology industry is in the same range as EDIT (32). This means that FATE’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITFATE
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
89%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
80%
Bullish Trend 17 days ago
87%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Nov 21, 2026
Stock price -- (EDIT: $1.71 vs. FATE: $1.01)
Brand notoriety: EDIT and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 72% vs. FATE: 109%
Market capitalization -- EDIT: $394.7M vs. FATE: $219.87M
EDIT [@Biotechnology] is valued at $394.7M. FATE’s [@Biotechnology] market capitalization is $219.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 1 FA rating(s) are green while FATE’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 1 green, 4 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 5 TA indicator(s) are bullish while FATE’s TA Score has 4 bullish TA indicator(s).

  • EDIT’s TA Score: 5 bullish, 5 bearish.
  • FATE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both EDIT and FATE are a good buy in the short-term.

Price Growth

EDIT (@Biotechnology) experienced а -20.09% price change this week, while FATE (@Biotechnology) price change was -24.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.90%. For the same industry, the average monthly price growth was -16.46%, and the average quarterly price growth was -27.70%.

Reported Earning Dates

EDIT is expected to report earnings on Feb 25, 2027.

FATE is expected to report earnings on Mar 01, 2027.

Industries' Descriptions

@Biotechnology (-8.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been closely correlated with BEAM. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-4.09%
BEAM - EDIT
68%
Closely correlated
-0.19%
CRSP - EDIT
63%
Loosely correlated
+0.44%
PRME - EDIT
62%
Loosely correlated
-7.55%
SLDB - EDIT
62%
Loosely correlated
-2.95%
VYGR - EDIT
61%
Loosely correlated
-4.97%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with CABA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then CABA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-9.01%
CABA - FATE
47%
Loosely correlated
-7.32%
SANA - FATE
46%
Loosely correlated
-8.62%
NKTX - FATE
45%
Loosely correlated
+1.34%
EDIT - FATE
44%
Loosely correlated
-4.09%
VCYT - FATE
44%
Loosely correlated
+0.36%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
MDT.X0.0037640.000031
+0.84%
Measurable Data Token cryptocurrency
REQ.X0.041191-0.001231
-2.90%
Request cryptocurrency
FIDA.X0.012579-0.000521
-3.98%
Bonfida cryptocurrency
EOS.X0.063857-0.003458
-5.14%
EOS cryptocurrency
LDO.X0.239994-0.019106
-7.37%
Lido DAO cryptocurrency